Emerging drugs for acute bacterial meningitis - Institut Pasteur Access content directly
Journal Articles Expert Opinion on Emerging Drugs Year : 2009

Emerging drugs for acute bacterial meningitis


The management of acute bacterial meningitis is based on early antibiotic treatment to prevent unfavorable outcome (death and permanent sequelae). beta-Lactam antibiotics, particularly third-generation cephalosporins, are effective against most agents of community-acquired acute bacterial meningitis. Resistance to beta-lactams evolves, particularly in Streptococcus pneumoniae, that may lead to treatment failure. Evaluation of other antibiotics such as fourth-generation cephalosporin, new penems and quinolones is warranted. Adjunctive therapy aims to reduce tissue injuries provoked by the inflammatory response. The use of dexamethasone is still a matter of debate, but seems to be helpful under conditions of rapid etiological diagnosis and prompt management. Other drugs that neutralize bacterial factors or host mechanisms involved in induction of inflammatory response are under development.


No file

Dates and versions

pasteur-03262202 , version 1 (16-06-2021)



Ala-Eddine Deghmane, Jean-Michel Alonso, Muhamed-Kheir Taha. Emerging drugs for acute bacterial meningitis. Expert Opinion on Emerging Drugs, 2009, 14 (3), pp.381-393. ⟨10.1517/14728210903120887⟩. ⟨pasteur-03262202⟩


13 View
0 Download



Gmail Facebook X LinkedIn More